Table 1 Comparison of the ganglioside-binding properties of AmyP53, wild-type and mutant α-synucleins.

From: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53

Peptide or protein

EC50 (µM ± SD)

AmyP53

0.53 ± 0.08

α-synuclein (wild-type)

1.78 ± 0.15

α-synuclein (A30P mutant)

1.05 ± 0.05

α-synuclein (E46K mutant)

1.18 ± 0.11

α-synuclein (A53T mutant)

1.08 ± 0.08

  1. Monolayers of ganglioside GT1b were prepared at the air-interface at an initial surface pressure of 17.5 mN/m. After equilibrium, AmyP53, the wild-type (wt) or the indicated mutant α-synuclein protein was added in the aqueous subphase underneath the monolayer at several concentrations (0.1–10 µM range). Surface pressure measurements were recorded in real-time until reaching a plateau value. The EC50 values (mean ± SD) were calculated from four independent measurements (p < 0.05 between AmyP53 and all α-synuclein proteins, and between wild-type and mutant α-synucleins in ANOVA test and post-hoc analysis).
Back to article page